Young, Tina C
Bristol-Myers Squibb (United States)
2 papers on CoChat
Most cited papers
- Verified
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017) · The Lancet Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 962
- Verified
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Choueiri, T. K., Fishman, M. N., Escudier, B., McDermott, D. F., Drake, C. G., Kluger, H., Stadler, W. M., Perez-Gracia, J. L., McNeel, D. G., Curti, B., et al. (2016) · Clinical Cancer Research
Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment
Cited by 295
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free